ES2071488T3 - Metodo para la purificacion de factor de crecimiento 1 analogo a la insulina intacto, correctamente plegado. - Google Patents

Metodo para la purificacion de factor de crecimiento 1 analogo a la insulina intacto, correctamente plegado.

Info

Publication number
ES2071488T3
ES2071488T3 ES92904088T ES92904088T ES2071488T3 ES 2071488 T3 ES2071488 T3 ES 2071488T3 ES 92904088 T ES92904088 T ES 92904088T ES 92904088 T ES92904088 T ES 92904088T ES 2071488 T3 ES2071488 T3 ES 2071488T3
Authority
ES
Spain
Prior art keywords
intact
purification
growth factor
insulin
analog
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES92904088T
Other languages
English (en)
Inventor
Gregory C Holtz
Russell A Brierley
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SIBIA Neurosciences Inc
Original Assignee
Salk Institute Biotechnology Industrial Associates Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Salk Institute Biotechnology Industrial Associates Inc filed Critical Salk Institute Biotechnology Industrial Associates Inc
Application granted granted Critical
Publication of ES2071488T3 publication Critical patent/ES2071488T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/65—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/20—Partition-, reverse-phase or hydrophobic interaction chromatography

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Analytical Chemistry (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Detergent Compositions (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

SE DESCRIBE UN METODO PARA LA RECUPERACION DE PEPTIDOS DE FACTOR-1 DE CRECIMIENTO DE LA INSULINA EQUIVALENTE MONOMERICA CORRECTAMENTE AISLADA E INTACTA, DESDE MEDIOS QUE CONTIENEN GRANDES CANTIDADES DE IGF-1. EL METODO COMPRENDE UNA SERIE DE PASOS DE ABSORCION Y EXPULSION, QUE EMPLEAN UNA COMBINACION DE ABSORBENTES DE INTERACCION HIDROFOBICA Y DE CAMBIO DE CATIONES. EL PEPTIDO IGF-1 PRODUCIDO ES ALTAMENTE PURO Y ES DESEABLE PARA EL USO EN UNA GRAN VARIEDAD DE APLICACIONES CLINICAS.
ES92904088T 1991-01-16 1992-01-15 Metodo para la purificacion de factor de crecimiento 1 analogo a la insulina intacto, correctamente plegado. Expired - Lifetime ES2071488T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US64143091A 1991-01-16 1991-01-16
US07/785,171 US5231178A (en) 1991-01-16 1991-10-28 Method for the purification of intact, correctly-folded insulin-like growth factor-1

Publications (1)

Publication Number Publication Date
ES2071488T3 true ES2071488T3 (es) 1995-06-16

Family

ID=27093753

Family Applications (1)

Application Number Title Priority Date Filing Date
ES92904088T Expired - Lifetime ES2071488T3 (es) 1991-01-16 1992-01-15 Metodo para la purificacion de factor de crecimiento 1 analogo a la insulina intacto, correctamente plegado.

Country Status (9)

Country Link
US (1) US5231178A (es)
EP (1) EP0567554B1 (es)
JP (1) JPH06505010A (es)
AT (1) ATE121099T1 (es)
AU (1) AU1194792A (es)
CA (1) CA2098183C (es)
DE (1) DE69202049T2 (es)
ES (1) ES2071488T3 (es)
WO (1) WO1992012993A1 (es)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5612198A (en) * 1990-09-04 1997-03-18 The Salk Institute Production of insulin-like growth factor-1 in methylotrophic yeast cells
ATE220105T1 (de) * 1991-04-01 2002-07-15 Merck & Co Inc Gene, die die proteolytische aktivitaet von pichia beeinflussen und deren verwendung
US5288931A (en) * 1991-12-06 1994-02-22 Genentech, Inc. Method for refolding insoluble, misfolded insulin-like growth factor-I into an active conformation
US5451660A (en) * 1993-12-13 1995-09-19 Genentech, Inc. Method for purifying polypeptides
US5446024A (en) * 1993-12-17 1995-08-29 Genentech, Inc. Purification of insulin-like growth factor
DE4405179A1 (de) * 1994-02-18 1995-08-24 Hoechst Ag Verfahren zur Gewinnung von Insulin mit korrekt verbundenen Cystinbrücken
WO1996007744A1 (en) * 1994-09-08 1996-03-14 Chiron Corporation A method of improved production of insulin-like growth factor
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
US5650496A (en) * 1995-04-14 1997-07-22 Cephalon, Inc. IGF-I purification process
US6756484B1 (en) * 1995-04-14 2004-06-29 Cephalon, Inc. IGF-I purification process
US7193042B1 (en) 1995-06-07 2007-03-20 Chiron Corporation Methods for purifying authentic IGF from yeast hosts
JP2002514890A (ja) * 1995-06-07 2002-05-21 カイロン コーポレイション 酵母宿主から真性のｉｇｆを精製するための方法
US7071313B1 (en) 1995-06-07 2006-07-04 Cephalon, Inc. Methods of purifying authentic IGF from yeast hosts
SE9504019D0 (sv) 1995-11-13 1995-11-13 Pharmacia Ab Method for production of proteins
US6767892B1 (en) * 1997-11-07 2004-07-27 Chrion Corporation Compositions providing for increased IGF-I solubility
DE69919701T2 (de) 1998-06-01 2005-09-15 Genentech, Inc., South San Francisco Abtrennung von antikörper-monomeren von deren multimeren mittels ionaustausch-chromatographie
JP2001218840A (ja) * 2000-02-14 2001-08-14 Kanegafuchi Chem Ind Co Ltd トランスフォーミング増殖因子βの吸着材、吸着除去方法および吸着器
US7537938B2 (en) * 2000-04-28 2009-05-26 Monogram Biosciences, Inc. Biomarker detection in circulating cells
US20040067498A1 (en) * 2000-04-28 2004-04-08 Ahmed Chenna Detection of nucleic acid sequences by cleavage and separation of tag-containing structures
US7771929B2 (en) * 2000-04-28 2010-08-10 Monogram Biosciences, Inc. Tag library compounds, compositions, kits and methods of use
AR036400A1 (es) * 2001-08-30 2004-09-08 Stem Cell Therapeutics Inc Regulacion combinada de la produccion de celulas nerviosas.
WO2003024472A2 (en) 2001-09-14 2003-03-27 Stem Cell Therapeutics Inc. Prolactin induced increase in neutral stem cell numbers and therapeutical use thereof
WO2003024471A2 (en) * 2001-09-18 2003-03-27 Stem Cell Therapeutics Inc. Effect of growth hormone and igf-1 on neural stem cells and therapeutic application
US6849394B2 (en) * 2002-02-21 2005-02-01 Minitube Of America Compositions comprising reproductive cell media and methods for using such compositions
CA2492442A1 (en) * 2002-07-31 2004-02-05 Stem Cell Therapeutics Inc. Method of enhancing neural stem cell proliferation, differentiation, and survival using pituitary adenylate cyclase activating polypeptide (pacap)
WO2005075498A1 (en) * 2004-01-30 2005-08-18 Amgen Inc. Process for purifying proteins
JP2007519422A (ja) 2004-02-02 2007-07-19 アンブレツクス・インコーポレイテツド 修飾されたヒト四螺旋バンドルポリペプチド及びそれらの使用
AU2005211847B2 (en) 2004-02-13 2011-02-24 Stem Cell Therapeutics Corp. Use of luteinizing hormone (LH) and chorionic gonadotropin (hCG) for proliferation of neural stem cells and neurogenesis
MXPA06014684A (es) * 2004-06-18 2007-02-12 Ambrx Inc Novedosos polipeptidos de enlace antigeno y sus usos.
AU2005327906B2 (en) * 2004-07-21 2010-05-13 Ambrx, Inc. Biosynthetic polypeptides utilizing non-naturally encoded amino acids
WO2006069246A2 (en) 2004-12-22 2006-06-29 Ambrx, Inc. Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides
ATE541934T1 (de) * 2004-12-22 2012-02-15 Ambrx Inc Zusammensetzungen von aminoacyl-trna-synthetase und verwendungen davon
SG161210A1 (en) 2004-12-22 2010-05-27 Ambrx Inc Methods for expression and purification of recombinant human growth hormone
AU2005322019B2 (en) * 2004-12-22 2010-08-26 Ambrx, Inc. Formulations of human growth hormone comprising a non-naturally encoded amino acid
BRPI0519430A2 (pt) 2004-12-22 2009-02-10 Ambrx Inc hormânio do crescimento humano modificado
KR20080026135A (ko) * 2005-06-03 2008-03-24 암브룩스, 인코포레이티드 개선된 인간 인터페론 분자 및 이의 용도
MX2008002149A (es) * 2005-08-18 2008-04-22 Ambrx Inc Composiciones de arnt y sus usos.
KR20080074108A (ko) 2005-09-27 2008-08-12 스템 셀 테라퓨틱스 코포레이션 프로락틴에 의해 조절되는 올리고덴드로사이트 전구체 세포증식
PT1954710E (pt) * 2005-11-08 2011-06-07 Ambrx Inc Aceleradores para a modificação de aminoácidos nãonaturais e polipeptídeos de aminoácidos não-naturais
EP2339014B1 (en) * 2005-11-16 2015-05-27 Ambrx, Inc. Methods and compositions comprising non-natural amino acids
KR101423898B1 (ko) * 2005-12-14 2014-07-28 암브룩스, 인코포레이티드 비-천연 아미노산 및 폴리펩티드를 함유하는 조성물, 비-천연 아미노산 및 폴리펩티드를 포함하는 방법, 및 비-천연 아미노산 및 폴리펩티드의 용도
KR20080106976A (ko) * 2006-03-17 2008-12-09 스템 셀 테라퓨틱스 코포레이션 신경 줄기 세포 증식제 및 신경 줄기 세포 분화제의 연속 투여 방법
EP2069396B1 (en) 2006-09-08 2015-10-21 Ambrx, Inc. Modified human plasma polypeptide or fc scaffolds and their uses
US8420792B2 (en) * 2006-09-08 2013-04-16 Ambrx, Inc. Suppressor tRNA transcription in vertebrate cells
NZ574721A (en) * 2006-09-08 2012-02-24 Ambrx Inc Hybrid suppressor trna for vertebrate cells
BRPI0809583B1 (pt) * 2007-03-30 2022-02-22 Ambrx, Inc Polipeptídeo fgf-21 modificado, composição compreendendo o mesmo, método para produzir o referido polipetídeo fgf-21 e célula compreendendo um polinucleotídeo
EP1988154B1 (en) 2007-04-30 2013-08-21 Ajinomoto Co., Inc. Method for producing human insulin-like growth factor I
CA2685596A1 (en) * 2007-05-02 2008-11-13 Ambrx, Inc. Modified interferon beta polypeptides and their uses
NZ603812A (en) * 2007-11-20 2014-06-27 Ambrx Inc Modified insulin polypeptides and their uses
SG188143A1 (en) 2008-02-08 2013-03-28 Ambrx Inc Modified leptin polypeptides and their uses
NZ591235A (en) * 2008-07-23 2012-07-27 Ambrx Inc Modified bovine g-csf polypeptides comprising non natural amino acid and their uses treating infections such as mastitis
PL2342223T3 (pl) 2008-09-26 2017-09-29 Ambrx, Inc. Zmodyfikowane polipeptydy zwierzęcej erytropoetyny i ich zastosowania
TR201802361T4 (tr) 2008-09-26 2018-03-21 Ambrx Inc Doğal olmayan amino asit replikasyonuna bağımlı mikroorganizmalar ve aşılar.
NZ600361A (en) 2009-12-21 2014-06-27 Ambrx Inc Modified bovine somatotropin polypeptides and their uses
CN104017063A (zh) 2009-12-21 2014-09-03 Ambrx公司 经过修饰的猪促生长素多肽和其用途
US9567386B2 (en) 2010-08-17 2017-02-14 Ambrx, Inc. Therapeutic uses of modified relaxin polypeptides
MY162837A (en) 2010-08-17 2017-07-31 Ambrx Inc Modified relaxin polypeptides and their uses
AR083006A1 (es) 2010-09-23 2013-01-23 Lilly Co Eli Formulaciones para el factor estimulante de colonias de granulocitos (g-csf) bovino y variantes de las mismas
CA2839570C (en) 2011-06-23 2020-04-07 Rho Renewables, Inc. Recombinant production systems for decarboxylated aromatic molecules
US9783570B2 (en) 2011-07-01 2017-10-10 Hoffmann-La Roche Inc. Method for separation of monomeric polypeptides from aggregated polypeptides
UY36370A (es) 2014-10-24 2016-04-29 Bristol Myers Squibb Company Una Corporación Del Estado De Delaware Polipéptidos fgf-21 modificados y sus usos
ES2963839T3 (es) 2017-02-08 2024-04-02 Bristol Myers Squibb Co Polipéptidos de relaxina modificados que comprenden un potenciador farmacocinético y usos de los mismos
WO2022097216A1 (ja) * 2020-11-05 2022-05-12 シミックホールディングス株式会社 組み換えインスリン様成長因子ｉの製造方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BG49718A3 (en) * 1983-07-15 1992-01-15 Bio Technology General Corp Method for preparing of polypeptid with superoxiddismutasne activitty
US4963665A (en) * 1986-01-07 1990-10-16 Washington University Human preproinsulin-like growth factor I
US4769361A (en) * 1986-08-07 1988-09-06 International Minerals & Chemical Corp. Method for purifying and isolating two ionic forms of somatomedin C
GB8819826D0 (en) * 1988-08-20 1988-09-21 Kabivitrum Ab Glycosylated igf-1

Also Published As

Publication number Publication date
AU1194792A (en) 1992-08-27
CA2098183C (en) 2000-09-05
DE69202049D1 (de) 1995-05-18
CA2098183A1 (en) 1992-07-16
DE69202049T2 (de) 1995-08-24
US5231178A (en) 1993-07-27
EP0567554B1 (en) 1995-04-12
WO1992012993A1 (en) 1992-08-06
ATE121099T1 (de) 1995-04-15
JPH06505010A (ja) 1994-06-09
EP0567554A1 (en) 1993-11-03

Similar Documents

Publication Publication Date Title
ES2071488T3 (es) Metodo para la purificacion de factor de crecimiento 1 analogo a la insulina intacto, correctamente plegado.
SG93893G (en) Homogeneous erythropoietin
WO1996030520A3 (en) Synthetic hpv6/11 hybrid l1 dna encoding human papillomavirus type 11 l1 protein
EP0410207A3 (en) Stabilization of highly purified proteins
GB8826451D0 (en) Improvements in/relating to organic compounds
EP0261554A3 (en) Process for the purification of 1,3-propane diol
ATE110704T1 (de) Verwendung von kohlenstoffmolekularsieben zur reinigung von chlorfluorkohlenwasserstoffen.
ES2105033T3 (es) Metodo de purificacion de proteinas.
DE60029542D1 (de) Verfahren zur Reinigung von 1,3-propandiol aus einem Fermentationsmedium
DE69132795T2 (de) Gereinigtes gp120, in dem seine natürliche konformation erhalten bleibt
ATE121077T1 (de) Neue organische nitrate und verfahren zu deren herstellung.
DE59303465D1 (de) Verfahren zur Reaktivierung eines bei der Herstellung von 1,1,1,2,3,3,3-Heptafluorpropan (R 227) eingesetzten Aktivkohle-Katalysators
CA2137676A1 (en) Purification of fullerenes
DE69313832D1 (de) Verfahren zur Herstellung von 2,4-Dihydroxydiphenylsulfon
FR2711323B1 (fr) Procédé d'élimination par adsorption d'hydrocarbures contenus dans l'air.
DE69206279D1 (de) Verfahren zur Herstellung von 2,6-Naphthalindicarbonsäure.
AU1239795A (en) Purified stable liquid prealbumin
DE69214937D1 (de) Verfahren zur herstellung von gereinigten 2,6-naphthalindicarbonsäuren
AU5024490A (en) Method of recovering purified epi protein from a solution especially a fermentation solution
CA2150225A1 (en) A process for the purification of natural pulmonary surfactant material using supercritical fluids
AU2478292A (en) Purification of factor xiii
AU3840695A (en) Novel alpha,alpha,alpha',alpha'-tetrachlorobicarboxylic acids, process for producing them and medicaments containing them
GB9307923D0 (en) Process for the purification of 1-chloro-2,2,2-trifluroethane
TH49831EX (th) หลอดบรรจุ
TH49834EX (th) หลอดบรรจุ

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 567554

Country of ref document: ES